Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Total Liabilities : $22.11 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Total Liabilities?

Clinuvel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was $22.11 Mil.

Clinuvel Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2022 ($14.25 Mil) to Jun. 2023 ($19.52 Mil) and increased from Jun. 2023 ($19.52 Mil) to Dec. 2023 ($22.11 Mil).

Clinuvel Pharmaceuticals's annual Total Liabilities increased from Jun. 2021 ($7.52 Mil) to Jun. 2022 ($12.92 Mil) and increased from Jun. 2022 ($12.92 Mil) to Jun. 2023 ($19.52 Mil).

Clinuvel Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Total Liabilities Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

3.59

5.43

7.52

12.92

19.52

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															5.98	12.92	14.25	19.52	22.11

Clinuvel Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Clinuvel Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.111	+	(0.469	+	0.049
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.851	+	0.038)
	=	19.52

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	130.009	-	110.491
	=	19.52

Clinuvel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.669	+	(0.477	+	0.1
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.863	+	0)
	=	22.11

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	141.687	-	119.578
	=	22.11

Clinuvel Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.